ClinicalTrials.Veeva

Menu

Influence of Different Approaches to Dietary Advising on the Effects of Acarbose Treatment in Obese Diabetic Patients Under Real-life Setting (CATERING)

Bayer logo

Bayer

Status

Completed

Conditions

Diabetes Mellitus

Treatments

Drug: Glucobay (Acarbose, BAYG5421)

Study type

Observational

Funder types

Industry

Identifiers

NCT01333774
GB0810PL (Other Identifier)
13928

Details and patient eligibility

About

It has been recently suggested, that not the diet by itself, but also patient's adherence to dietary recommendations and all actions performed to improve dietary compliance, may be a significant factor influencing blood glucose control. There are no clinical data on the influence of different approaches to dietary advising on the effects of acarbose treatment in obese diabetic patients under real-life setting in Poland. Thus, the aim of this study was to assess the influence of different approaches to dietary advisory on the effects of acarbose treatment (reflected by changes in HbA1c) in obese DM patients. We also intended to assess the influence of different approaches to dietary advising on the appearance of potential adverse events in acarbose treated obese DM patients.

Enrollment

423 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • type 2 diabetes
  • age>18 years

Exclusion criteria

  • Hypersensitivity to acarbose or any of the excipients
  • age<18
  • pregnancy and in nursing
  • inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction
  • chronic intestinal diseases associated with marked disorders of digestion or absorption
  • states which may deteriorate as a result of increased gas formation in the intestine, (e.g. Roemheld's syndrome [an angina pectoris-like syndrome or aggravation of an angina pectoris due to the post-prandial filling of the stomach] and larger hernias)
  • hepatic and severe renal impairment (creatinine clearance <25 mL/min/ 1,73m2)

Trial design

423 participants in 1 patient group

Group 1
Treatment:
Drug: Glucobay (Acarbose, BAYG5421)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems